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Abstract
Background: Hyperresponsiveness to inhaled non-infectious microbial particles (NIMPs) has been associated with illnesses
in the airways. Hypersensitivity pneumonitis (HP) is considered to be the prototype for these NIMPs-related diseases;
however, there is no consensus on the definitions or diagnostic criteria for HP and the spectrum of related illnesses.
Methods and Findings: In order to identify the possible diagnostic markers for illnesses associated with NIMPs in alveolar
lining fluid, we performed a proteomic analysis using a two-dimensional difference gel electrophoresis on bronchoalveolar
lavage (BAL) fluid from patients with exposure to NIMPs in the context of damp building-related illness (DBRI) or conditions
on the borderline to acute HP, designated here as agricultural type of microbial exposure (AME). Samples from patients with
HP and sarcoidosis (SARC) were included for reference. Results were compared to results of healthy subjects (CTR). Western
blot was used for validation of potential marker proteins from BAL fluid and plasma. Protein expression patterns suggest a
close similarity between AME and HP, while DBRI was similar to CTR. However, in DBRI the levels of the inflammation
associated molecules galectin-3 and alpha-1-antitrypsin were increased. A novel finding emerging from this study was the
increases of semenogelin levels in BAL fluid from patients with AME, HP and SARC. Histone 4 levels were increased in AME,
HP and SARC. Elevated plasma levels of histone 2B were detected in HP and SARC, suggesting it to be a potential blood
indicator for inflammatory diseases of the lungs.
Conclusions: In this study, the proteomic changes in bronchoalveolar lavage of DBRI patients were distinct from other NIMP
exposure associated lung diseases, while changes in AME overlapped those observed for HP patient samples. Some of the
proteins identified in this study, semenogelin and histone 4, could function as diagnostic markers for differential diagnosis
between DBRI and HP-like conditions.
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Introduction
Certain occupations and surroundings increase the risk of
exposure to inhaled non-infectious microbial particles, referred to
as NIMPs in this article. NIMPs contain microbial cell wall
structures and other microbial components, which are not
infectious, but can activate immune response via Toll-like
receptors and other pattern recognition receptors [1,2]. Working
in an agricultural environment, especially handling of moldy hay
or grain, exposes farm workers to NIMPs. The exposure to the
indoor air in damp buildings, will also cause exposure for NIMPs.
Hypersensitivity pneumonitis (HP), is a well-known yet complex
syndrome associated with the exposure to NIMPs. HP is an
inflammatory disease of the lung alveoli caused by exposure to a
wide range of airborne substances: bacteria, fungi, even inorganic
materials like certain chemicals. In some cases HP can also be
caused by exposure to damp buildings [3]. Only a small portion of
those exposed (1–15%), develop HP [4,5]. According to a two hit
hypothesis suggested to explain this: genetic factors (first hit) and
exposure patterns (second hit) are required for the NIMP exposure
to cause HP [6].
At least four separate sets of differing diagnostic criteria are
currently in use for HP evaluation [7]. HP is traditionally divided
in acute, subacute and chronic forms although there is no
generally accepted definitions of these different and often
overlapping forms of HP [6,7], despite the long diagnostic history
of this disease. Substantial diagnostic problems are also encoun-
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tered with the severe fibrosing forms of HP which start to resemble
other forms of interstitial pulmonary fibroses and with the less
severe HP-like conditions which however do not fulfil all of the
diagnostic criteria [8].
Damp building-related illness (DBRI) is a much less well-
established illness than HP, even though a consensus exists that
dampness and mould in buildings are a risk factor for health [9–
11]. DBRI has been typically associated with prolonged exposure
to water-damaged buildings, as in the case of the HP only some of
those exposed will develop symptoms [12,13]. The DBRI-
associated symptoms tend to be diverse: fever, headache, myalgias,
and respiratory symptoms like cough that in some respects
resemble HP. After the initial phase an exposure to a damp
building can result in persistent respiratory symptoms, especially
asthma and increased sensitivity to quality problems in the indoor
air (possibly due to sensitization to the organic or inorganic
compounds associated with indoor air in damp buildings) even
though the primary source of the exposure has been eliminated
[14,15]. There are no well-defined diagnostic criteria for DBRIs,
and DBRI-specific diagnostic laboratory tests are lacking. Earlier
studies of our group have shown that exposure to conditions of
damp buildings increased lymphocyte levels in the BAL fluid of
DBRI patients [16]. There is no specific quantity or quality of
NIMPs which can be stated to designate an exposure state causing
significant health effects. In other words, no specific causal agents
of adverse health effects in damp buildings have yet been identified
conclusively [11,17].
Bronchoalveolar lavage (BAL) is widely used to obtain
diagnostic information about interstitial lung diseases (ILDs)
[18]. The BAL procedure provides unique insights into the
condition of the alveolar spaces and thus BAL findings, like
immune cell patterns, play an important role in supporting the
diagnosis of interstitial lung diseases when combined with other
clinical data and thoracic tomography [19].
Previous studies have reported that pulmonary disorders such as
idiopathic interstitial fibrosis, sarcoidosis and asthma alter the
protein composition of bronchoalveolar lavage [20,21]. Analysis of
BAL sample by two-dimensional gel electrophoresis has been
shown to be a useful way of studying the pathogenesis of lung
diseases [22–24].
This study originated from the clinical differential diagnostic
problems posed by DBRI on the one hand and on the other
agricultural NIMP exposures (AME) that often do not meet the
criteria for HP. The study had two goals, the first was to examine
the proteomic changes in alveolar lining fluid in conditions where
exposure to NIMPs had resulted in a pathologic condition in order
to discover possible diagnostic markers for this type of illness. The
second goal was to examine the relationship between HP, AME
and DBRI from a proteomic point of view.
We collected BAL fluid from patients with DBRI or AME with
symptoms and findings that mostly fall short of classic HP. In
addition, samples from HP patients were used as the reference
material of an established lung disease associated with inhaled
NIMPs, while samples from sarcoidosis (SARC) patients served as
the reference material for a lung disease in which there is no direct
association with NIMP exposure. Finally healthy non-smoking
subjects served as controls. The two-dimensional difference gel
electrophoresis (2D-DIGE) was used to identify the differences in
protein expression between BAL fluids from different patient
groups. Potential biomarker proteins were validated with Western
blotting. The results revealed a clear difference in the protein
expression patterns of alveolar lining fluid between DBRI and the
other NIMP exposure associated groups: AME and HP. Four
potential biomarkers (alpha-1-antitrypsin, galectin-3, histone H4,
semenogelin I) were identified and these may be useful in
monitoring the inflammatory state of the lung diseases after
NIMP exposure, although the markers do not appear to be specific
for illnesses associated with NIMPs.
Materials and Methods
Patients and collection of the BAL and plasma samples
BAL samples were from patients examined in the Finnish
Institute of Occupational Health (FIOH) in 1997–2008. The
patients had been sent to the occupational diseases clinic at the
FIOH because of suspicion of occupation related respiratory
diseases. The study targeted non-smoking patients with chronic
symptoms (for more than one year) compatible with DBRI (n = 17)
or symptoms related to agricultural exposure (AME, n = 9) for
NIMPs. Those patients who had been treated with oral steroids
during the past two months were excluded. An occupational
physician experienced in indoor air problems conducted a
retrospective evaluation of each patient’s exposure at work on
the basis of available documents in the patient records. For the
patients in the DBRI group, the documents included reports on
building structure damage and, in most instances, microbial
measurements of structural materials taken from the building. In
order to be included in the study, the exposure to NIMPs had to
be evaluated as being clear and significant. For the patients in the
agricultural exposure group, AME, the criterion for NIMP
exposure was handling of organic moldy material.
BAL fluids from patients with HP (n = 10) served as the
reference material for an established lung disease associated to
NIMPs, and sarcoidosis (n = 11), served as the reference material
for a lung disease with no direct association with NIMPs, these
specimens had been collected in an earlier study from the Meltola
Hospital (a former pulmonary hospital) [25]. For HP the
diagnostic criteria according to Terho [26] were used. In all of
the HP cases acute symptoms were present and the illnesses can be
considered to be in an acute phase [27]. The control group (CTR)
of this study comprised of healthy individuals from the personnel
of the Meltola Hospital (n = 16) and FIOH (n = 4) with no smoking
histories. All tested plasma samples (available from CTR, HP and
SARC groups) were from the Meltola Hospital. The remainder of
the healthy controls had been obtained at the FIOH in year 2001
(n = 4/20). Both of these samplings of healthy controls were used
in 2D-DIGE analysis. In the Western blot validation studies, six
BAL samples from healthy volunteers from FIOH with positive
smoking histories served as an additional control group for
monitoring the effect of smoking.
In all cases the bronchoalveolar lavage was performed as
described in [28]. After pooling of the BAL fluid, a 20 ml sample
was separated and centrifuged at 1000 rpm for 5 minutes. The
supernatant was frozen at 220uC. Sample freeze-thaw cycles were
avoided by using sample aliquots. Both controls and disease
samples were stored similarly. The investigated BAL samples were
free of excessive blood- or epithelial contamination [25]. Patient
characteristics and additional information about the BAL fluid
content are given in Table 1. Major symptoms and high-resolution
computed tomography (HRCT) findings of the DBRI and AME
group patients are described in Table 2. Written consent for
participation in this study was obtained for the samples taken from
FIOH patients. The samples of patients from Meltola hospital
were originally intended for and used in a different study and
written or verbal consent was not required for this study. The
Coordinating Ethics Committee at the Hospital District of
Helsinki and Uusimaa reviewed and approved the study protocols
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including the use of the samples from the Meltola hospital (Diary
number 320/13/03/00/09).
2-DIGE and DeCyder analysis
Four-to six samples per study group were used in the 2D-DIGE.
About 10 ml of each BAL sample was concentrated with
ultrafiltration (Amicon Ultra-15 5000 MWCO, Millipore, Ireland)
to 100 ml. The sample was then depleted of albumin and
immunoglobulin G to facilitate higher sample loading, and to
improve detection of low-abundance proteins. This procedure was
done with the ProteoPrep Immunoaffinity Albumin and IgG
Depletion Kit (Sigma Aldrich, St. Louis, MO, USA) according to
the manufacturer’s protocol. After the determination of the
protein concentration (BioRad kit) BALF proteins were precipi-
tated with 2-D Clean-Up Kit (GE Healthcare) and dissolved to a
protein concentration of 2 mg/ml in 7 M urea, 2 M thiourea, 4%
CHAPS (Anatrace, Maumee, OH, USA) and 30 mM Tris-HCl,
pH 8.8. Then, 10 ml from each sample was pooled for the internal
Table 1. Patient characteristics.
Diagnosis DBRIa AMEb HPc SARCd Controls In total
No. of cases (%) 17 (25.4) 9 (13.4) 10 (14.9) 11 (16.4) 20 (29.9) 67
Male# (%) 3 (17.6) 3 (33.3) 8 (80) 4 (36.4) 9 (45) 27 (40.3)
Female# (%) 14 (82.4) 6 (66.7) 2 (20) 7 (63.6) 11 (55) 40 (59.7)
Age
Median 48 47 54 48 35 45
Mean (SD) 48 (8) 48 (6) 53 (10) 45 (13) 36 (9) 45 (11)
Range 34–61 41–57 33–68 27–65 22–52 22–68
Albumin mg/l BALfluid
Median 30 36 39 66 23 33
Mean (SD) 36 (22) 47 (29) 67* (63*) 82 (48) 23* (9*) 51 (24)
Cells610E6/l BALfluid
Median 122 278 280 114 125* 146
Mean (SD) 140 (73) 281 (127) 367 (340) 178 (111) 128 (61)* 200 (176)
Lymphocytes %
Median 20 28 52 35 18* 22
Mean (SD) 25 (16) 31 (26) 52 (21) 26 (15) 18 (9)* 29 (20)
Neutrophils %
Median 3* 2 2* 1* 1** 1
Mean (SD) 3 (3)* 6 (9) 3 (3)* 1 (1)* 2 (3)** 3 (5)
*Data available for $80% of samples.
**Data available for $75% of samples.
aDamp building-related illness.
bAgricultural type of microbial exposure.
cHypersensitivity pneumonitis.
dSarcoidosis.
doi:10.1371/journal.pone.0102624.t001
Table 2. Major symptoms and HRCT findings.
DBRI n=17 AME n=9
Cough 14 8
Dyspnea 13 8
Fever and chills 15 9
Duration of symptomsa
0–5 years 9 6
6–10 years 4 1
.10 years 4 2
Asthma diagnosis 8 2
HRCTb findings compatible with HPc/HRCT made none/12 3/9
abefore BAL procedure.
bHRCT= high-resolution computed tomography.
cHypersensitivity pneumonitis.
doi:10.1371/journal.pone.0102624.t002
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standard and 40 mg of BALF proteins were labelled using 200
pmol Cy3 or Cy5 dyes (CyDye DIGE Fluor minimal dyes; GE
Healthcare) according to the Ettan 2-D DIGE instructions. The
Cy2 dye was used as an internal standard whereas Cy3 and Cy5
labellings were randomized evenly between study groups. For each
combined Cy3- and Cy5-labelled sample pair, 40 mg of Cy2-
labelled internal control sample was added prior to the quantita-
tive 2D-DIGE analysis. CyDye labelled protein samples were
separated by isoelectric focusing (IEF) using IPG strips (13 cm, pH
3–10 NL, GE Healthcare). The IEF strips were rehydrated 6
hours in 250 mL of the rehydration solution (7 M urea, 2 M
thiourea, 4% CHAPS, 0.04% bromophenol blue (BPB) containing
0.5% IPG buffer, pH 3–10 NL (GE Healthcare) and 1.2%
DeStreak reagent (GE Healthcare). Samples were absorbed onto
the IPG strips by cup-loading. IEF was performed using Ettan
IPGphor II (GE Healthcare) at 20uC using a limit of 75 mA/strip
as follows: 3 hrs at 150 V, 2 hrs at 300 V, a linear gradient from
300 V to 1000 V for 6 hrs, the 2nd gradient from 1000 V to
8000 V for 2 hrs and finally 2 hrs at 8000 V (total 29 000 Vhrs).
Strips were stored at 220uC and thawed at room temperature just
before the SDS-PAGE analysis. They were incubated first for
15 min in a buffer containing 50 mM Tris–HCl (pH 6.8), 6 M
urea, 2% SDS, 0,04% BPB and 30% glycerol with 1%
dithiothreitol (DTT), followed by a 15 min equilibration in the
same buffer with 2% iodoacetamide (IAA) instead of DTT. The
two-dimensional SDS-PAGE was run on Criterion PreCast gels
(10–20% gradient Tris–HCl gels, BioRad) in a Criterion Dodeca
Cell (BioRad) with 200 V for approximately 75 minutes. Gels
were scanned between low fluorescence glass plates using an Ettan
DIGE Imager (GE Healthcare) at wavelengths of 480 nm for Cy2,
540 nm for Cy3 and 680 nm for Cy5 with 100 mm pixel size. After
scanning, the gels were fixed in 30% ethanol, 1% acetic acid and
silver stained [29]. The cropped images of 2-D DIGE gels were
analyzed for differences in protein expression by means of internal
Cy2 labelled standard using DeCyder 2D 7.0 software (GE
Healthcare). Gel spots with at least a 1.5-fold spot volume ratio
change and a Student’s t-test p value below 0.05 were picked for
identification.
Protein identification
Significantly up- or down-regulated protein spots were in-gel
digested as previously described [30]. In brief, the protein spots
were excised from the gels, reduced with dithiothreitol, and
alkylated with iodoacetamide before in-gel digestion with trypsin
(modified sequencing grade porcine trypsin, 0.04 mg/ml, Promega,
Madison, WI, USA) for 16 h at +37 uC. After removing the
supernatants to fresh tubes, the remaining peptides were extracted
twice from the gel pieces by using 100 ml of 5% formic acid in
50% acetonitrile (ACN). The extracts were then dried in a vacuum
centrifuge, and dissolved in 2% formic acid. Each peptide mixture
was analyzed with an automated nanoflow capillary LC–MS/MS
using CapLC system (Waters, Milford, MS, USA) coupled to an
electronspray ionization quadrupole time-of-flight (Q-TOF) mass
spectrometer (Waters). Reversed phase separations were accom-
plished with a 75 mm615 cm NanoEase Atlantis dC18 column at a
flow rate of 200 nl/min. Solvent A was 0.1% formic acid in 5%
ACN, and solvent B 0.1% formic acid in 95% ACN. The peptide
separation was achieved with a linear gradient of 0–60% of solvent
B in 30 min.
The obtained mass fragment spectra were analyzed with in-
house Mascot v.2.1 (Matrix Science Ltd., London, UK) and
searched against human or mammalian entries in the NCBInr
database. One missed cleavage was allowed, and searches were
performed with fixed carbamidomethylation of cysteines, and
variable oxidation of methionine, histidine, and tryptophan
residues. A fragment tolerance of 0.2 Da and parent tolerance of
0.5 Da were used with trypsin as the specified digestion enzyme. A
minimum number of two matched peptides or a Mascot score
higher than 70, was considered significant.
DeCyder Extended Data Analysis and GO classification
DeCyder Extended Data Analysis software (Version 7.0, GE
Healthcare) was used for multivariate analysis of protein expres-
sion and protein Gene Ontology –classification based on the
DeCyder 2D 7.0 software data of identified proteins. Protein spots
not presented in at least 75% of the spot maps were removed from
the analysis. Protein enrichment analysis was performed with a
functional annotation tool: DAVID Bioinformatics Resources 6.7.
(http://david.abcc.ncifcrf.gov/).
Western blot
The relative protein expression of semenogelin I, histones 2B
and 4, alpha-1-antitrypsin and galectin-3 in BALF (62 samples)
and in plasma (37 samples) were evaluated by Western blot
analysis to validate proteins identified from 2-DIGE and DeCyder
analysis.
Volumes of 15 ml of BALF samples or 1.5 ml of plasma were run
on 10–20% Tris-HCl Criterion gradient gels (Bio-Rad) at 100 V
for 5 minutes, and 200 V for 60 minutes in running buffer
(Biorad) of 25 mM Tris pH 8.3, 192 mM glycine and 0.1% SDS.
A pool of all of the BALF or plasma samples was used as an
internal standard on each gel to provide a reference from which to
normalize the results. Two different molecular weight markers,
Dual Color (Biorad) and MagicMark (Invitrogen, Carlsbad, CA,
USA), were used in order to improve detection and analysis of
protein bands. Proteins were transferred to polyvinylidene
difluoride membranes (Millipore, Billerica, MA, USA) using the
Criterion Blotter (Biorad) at 300 mA for 2 h in transfer buffer
(25 mM Tris, 192 mM glycine, 20% methanol). Membranes were
blocked with 5% skimmed milk in PBS, and incubated in a tube
roller for 18 h at +4uC with polyclonal primary antibodies histone
H4 (HIS4, anti-rabbit, dilution 1:500) from Cell Signaling
Technology, histone H2B (HIS2B, anti-rabbit, 1:2000) and
semenogelin I (SEM, anti-rabbit, 1:1000) from Abcam, galectin-
3 (GAL3, anti-rabbit, 1:500) from Santa Cruz Biotechnology Inc
and anti-a1-antitrypsin (a1AT, anti-mouse, 1:4000) from AbFron-
tier. The Histone H2B antibody produced at best a weak signal in
Western blots made from BAL samples. Only results obtained with
the histone antibody H4 are shown for BAL samples. The H4
antibody did not produce any signal with the plasma samples (data
not shown). Immunoblots were stained with polyclonal goat anti-
rabbit or anti-mouse peroxidase-conjugated immunoglobulins
(Dako Cytomaton, Glostrup, Denmark) and visualized with
chemiluminescent HRP-substrate ECL detection reagent (Perkin
Elmer, Waltham, MA, USA). The blots were imaged with
ImageQuantLAS 4000 mini, software version 1.0 (GE Health-
care). Quantitation of the protein bands on immunoblots was
accomplished by calculating the intensities of the bands with image
analysis software v.7.0 ImageQuant TL from GE Healthcare.
Statistical analyses were performed using GraphPad Prism 5
software (GraphPad Software). A Mann-Whitney U test was used
to compare the differences between the groups, since neither BAL
nor plasma data is not normally distributed. A p value of ,0.05
was considered to be statistically significant.
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ELISA measurements
IgG ELISA assay for the BAL samples was performed following
the manufacturers instructions (eBioscience, San Diego, CA,
USA). ELISA assay detected the total amounts of IgG.
Results
Proteomic analysis of bronchoalveolar lavage after
exposure to inhaled NIMPs
Screening of potential biomarkers was performed for a total of
24 BAL samples from the healthy control (CTR n = 6) and four
disease groups (AME n = 5, DBRI n = 5, HP n = 4, and SARC
n = 4). DeCyder software detected on average 2000 spots per
DIGE gel. A total of 63 proteins spots and 34 different proteins
were identified from the selected gel spots (Figure 1 and Table S1),
which were differentially expressed (Students t –test ,0.05, a fold
change #21.5 or $1.5) between CTR versus one or all of the
study groups (AME, DBRI, HP, SARC). Some of the differences
were obtained also from the comparisons between DBRI versus
AME. According to the Gene Ontology classification, most of the
proteins were grouped as belonging to the extracellular region.
One third of the proteins were associated with antigen binding.
Identified proteins were also associated with protein binding,
serine-type endopeptidase activity, ferric iron binding and DNA
binding (Figure 2A). The outcome of the classification of proteins
in biological processes pointed to the following categories: immune
response, function of platelets, cellular iron ion homeostasis,
transmembrane transport and response to reactive oxygen species
(Figure 2B). Based on the protein enrichment analysis, extracel-
lular secreted proteins, especially plasma proteins, were abundant
among the identified proteins from the BAL samples (Table S2).
Most of the proteins were also classified as glycoproteins, a
common property of human biofluid proteins, and they contained
a signal peptide for secretion.
Differences in protein expression pattern of damp
building-related illness in comparison to the other NIMP
exposed groups
A hierarchical clustering was performed for the 63 identified
proteins to compare the protein expression patterns between the
experimental groups (Figure 2C). The CTR, DBRI and SARC
study groups formed one main cluster with the other main cluster
being comprised of AME and HP. Control and DBRI formed
their own subgroup which excluded SARC, i.e. evidence that
there was a similar overall protein expression patterns between
these two groups. Marked upregulation of proteins was observed
in the AME and HP experimental groups, and this feature
distinguished these two groups from the other main cluster. The
clustering of the spot maps according to the variance of their
protein expression was performed with principal components
analysis (Figure 2D). The homogeneity or heterogeneity of the
protein abundance within and between the study groups is
visualized in the format of a heatmap in Figure S1. The
lymphocyte percentage of BAL samples chosen for DIGE analysis
from DBRI group differed from the control samples (Student’s t -
test ,0.05), but not from the other disease group samples (Figure
S2).
The proteins, which have 1.5 times lower or higher expression
in study groups compared to control group are represented in
number sets by the Venn diagram (Figure S3). Information about
the identified proteins is shown in table S1.
Haptoglobin (HPT, this abbreviation refers to the abbreviation
used in Table S1), histone variants, immunoglobulin G (IGHG2,
IGHG1) and semenogelin (SEMG1) were overexpressed in all
disease groups. None of the identified proteins were less abundant
in DBRI as compared to CTR group. Two proteins, a component
of the class I major histocompatibility complex, beta-2-micro-
globulin (B2MG) and an intracellular cholesterol transporter,
epididymal secretory protein E1 (NPC2) were downregulated in
AME, HP and SARC compared to control group.
Peroxiredoxin 5 (PRDX5) appeared to be underexpressed in
SARC patients. Apolipoprotein A1 (APOA1) was upregulated in
all microbial-associated lung conditions, but not in SARC.
None of the proteins in DBRI group seemed to be characteristic
to that particular condition. The expression of protein S100-A8,
which is a part of calprotectin, an acute phase reactant in
inflammation, was elevated only in AME as compared to healthy
persons. The amounts of complement factor B (CFAB) selenium
binding protein (SBP1) and hemopexin (HEMO) were markedly
increased, whereas those of superoxide dismutase (SODC) and
thioredoxin (THIO) were reduced in HP compared to control.
However, the levels of these proteins in AME and HP did not
differ significantly from most of the other disease groups (data not
shown).
Pulmonary surfactant proteins have been linked to innate
immunity of the lung helping to prevent the infection and
inflammation. However, no statistically significant differences in
the expression of the identified surfactant proteins (SP-A and D)
were detected between studied samples.
Validation of potential indicators for NIMP associated
lung diseases
The original reason for the study was to identify markers for
diseases associated with the exposure to NIMPs, however, we did
not find this type of marker (i.e. those displaying consistent
increases over control levels in the DBRI, AME, and HP but not
the SARC group; preferably so that the marker would not be
implicated in other inflammatory conditions). In the validation
study we concentrated on those markers that increased with
reasonable robustness compared to the healthy controls. An
additional restriction for western blot validation was provided by
the availability and functionality of antibodies. Four proteins were
chosen for immunological validation and quantitation: alpha-1-
antitrypsin, galectin-3, histone H4 and semenogelin 1 (Figure 3).
Alpha-1-antitrypsin (A1AT) is a protease inhibitor; its levels may
increase in the lungs during the inflammation and dysfunction of
this protein has been claimed to be associated with several
respiratory conditions. All the patient groups had significantly
elevated A1AT levels as compared to healthy controls according to
immunoblot quantitation results. The highest amounts of A1AT
were detected in samples from HP patients (Figure 3C).
Galectin-3 has important roles in the innate immunity response
such as the activation and chemoattraction of inflammatory cells.
The levels of this protein were upregulated in HP and AME
groups based on DeCyder analysis (Figure 3A, Table S1),
indicating that it is one of the proteins acting similarly in these
two hierarchical linked groups. Immunoblot revealed that there
were significant changes between the experimental groups and
healthy controls. The highest levels of galectin-3 were seen in
AME patients (Figure 3C). There were no significant changes
between the experimental groups (AME, DBRI, HP, SARC),
when they were compared to each other.
Semenogelins are proteins which are known to participate in the
formation of sperm coagulum. However, semenogelins have also
been reported to be present in the lungs and in small cell lung
carcinoma [31]. Based on DeCyder analysis, the level of
semenogelin was upregulated in all of the studied disease patient
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groups (Figure 3A, Table S1). The immunoblot validation verified
that the levels of semenogelin were markedly increased in AME,
HP, and sarcoidosis patients as compared healthy controls. In the
DBRI group, there was no significant difference in semenogelin
abundance as compared to healthy controls (Figure 3C). The
difference between DBRI and AME/HP was significant
(p = 0.0009 for DBRI vs. AME and p = 0.0001 for DBRI vs. HP).
Histones are core components of nucleosomes and can boost
inflammatory response by functioning as endogenous danger
signals in our immune system [32]. Histone variants H2B and H4
were upregulated in all previously mentioned experimental
groups, albeit less in DBRI according to differential expression
analysis (Figure 3A, Table S1). The detected histones in BAL
samples were aberrant in size. The spots of 20–25 kDa and 40–
45 kDa size were identified as histones H4 and H2B in 2DE-
DIGE gel analysis in the human BALF samples. The immunoblot
based quantitation analysis of histone H4 in BAL fluid was
performed on a protein band of approximately 50 kD (H2B was
not measurable, see materials and methods). This aberrant size
histone detection with the histone primary antibody used was
confirmed by mass spectrometric analysis for this particular band
from the immunoblot membrane. The increased amount of
histone H4 in BAL fluid was associated with AME, HP and SARC
(Figure 3C). The difference between DBRI and AME/HP was
Figure 1. The false color image of two-dimensional DIGE gel of BAL. The gel image represents the Cy3 labeled (red), Cy5 labeled (blue) and
Cy2 labeled (yellow) patient samples. The latter is a pooled sample, which served as an internal standard. Spot abbreviations refer to the identified
proteins listed in Table S1. Molecular weights are shown on the right edge of the gel and the pI range on the top part of the SDS-PAGE.
doi:10.1371/journal.pone.0102624.g001
Inhalation of Non-Infectious Microbial Particles: BAL Proteomics
PLOS ONE | www.plosone.org 6 July 2014 | Volume 9 | Issue 7 | e102624
statistically significant (p = 0.01 for DBRI vs. AME and p = 0.0031
for DBRI vs. HP).
All the patients in the studied groups were nonsmokers. We also
investigated the effect on smoking on the proteins selected for
validation. Western blotting based validation was performed for
six BAL samples obtained from healthy controls with smoking
backgrounds. Only the levels of galectin-3 were elevated in a
group of smokers as compared to controls (CTR), p = 0.0482 (data
not shown).
To study the immunoglobulin response in lungs of patients
exposed to microbial particles the concentration of total IgG was
measured with ELISA assay from native BAL. The elevated
immunoglobulin levels were observed in BAL fluids from the
AME, HP and SARC groups (Figure S4).
Elevated histone levels in plasma samples of
hypersensitivity pneumonitis and sarcoidosis
Histone H2B and galectin-3 levels were also analyzed from
plasma samples of patients from control, HP and SARC groups.
Validation of other chosen protein markers produced inconsistent
results (data not shown), possibly due to interference of the similar
size serum albumin or to low levels of target protein. There were
no significant differences between the groups in galectin-3 levels,
however, H2B levels were markedly higher in plasma of HP and
SARC (Figure 4). Between HP and SARC there were no
significant differences in the abundance of H2B. In plasma, the
size of the histone H2B detected was 17 kDa, the predicted size of
histone when it is a part of the nucleosome.
Discussion
The results from the 2D gel analysis and the immunoblot
validation studies point to a substantial difference in protein
expression between the DBRI group and the AME/HP group.
Similar protein expression patterns of AME and HP samples
suggest there is a close association between AME and HP, while
the protein expression pattern of DBRI resembled more that of
healthy individuals and the SARC group.
Figure 2. Protein classification and study group clustering. Classification of the proteins for the different gene ontologies: (A) molecular
functions and (B) biological processess. The groups including $4 proteins from the set are depicted in the picture. (C) The hierarchical clustering of
the study groups is displayed in the form of a heatmap. A dendrogram at the top of the heatmap represents a hierarchy of studied groups based on
the degree of similarity in their protein expression. The heatmap shows the mean of a proteins expression on all analysed spot maps in that particular
experimental group. The protein expression levels of 63 identified proteins in the study groups are compared to levels of internal standard, red colour
indicating upregulation and green colour indicating underregulation. Data clustering is based on Pearson distance (Pearson correlation, average
linkage). (D) The clustering of the spot maps according to the variance of their protein expression was performed with principal components analysis.
The first principal component (PC1) explained 59.8% of the variance and the second (PC2) 12.8%. Cumulative variance 90% was reached after 7
components.
doi:10.1371/journal.pone.0102624.g002
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Comparing then NIMP associated illnesses in order to
understand the differences in proteomic outcome, they share a
similar general pattern of symptom free periods followed by
exacerbations when exposed to the appropriate NIMPs. In this
study the time from the start of symptoms to the BAL procedure
for DBRI and AME were comparable. The main difference is that
in DBRI, the exposures are known to be substantially less intense
than those experienced by subjects in the HP or AME groups and
this could be a part of the explanation. The major symptoms for
both DBRI and AME were fairly similar in this study, but there is
a difference in that asthma is more often present in DBRI. In the
literature HP is associated with a limited set of symptoms (fever,
cough, dyspnoea) while the symptoms of DBRI are very variable
and include symptoms from the upper airways, the nasal area, eyes
and skin. A relatively obvious explanation for the differences
between DBRI and HP is that they could affect separate parts of
the airways, HP is known to affect the alveolar spaces while DBRI
seems to affect the more proximal airways.
This study intended to resolve the diagnostic problems
associated with DBRI and AME in our clinic. In order to provide
reference material from HP and SARC, which are rarely
encountered at the FIOH clinic, we used BAL samples collected
from an earlier study [25]. HP is becoming a rarity in Finland and
we consider ourselves fortunate to have access to these samples.
The samples have been collected using an identical protocol to
that used in the FIOH. All the samples have been stored and
Figure 3. Immunoblot validation of protein markers in BAL. (A) Differential expression analysis based on DeCyder data for chosen protein
markers. Every dot indicates the identified protein spot and its expression level in that particular study group. The difference in protein expression
(average expression) between the groups is visualized with a continuous curve. Histone and semenogelin plots contains more than one curve due to
several protein spot identification for histones H4, H2B (n = 3) and semenogelin I (n = 2) as shown in Table S1. (B) Images of immunoblot membranes
and (C) immunoblot based validation results for protein markers. The number of samples in validation: CTR n= 19, AME n= 7–9, DBRI n = 17, HP n= 9,
SARC n=8. The means (black lines) are shown in scatter plots. *Indicates statistical significance, which is shown between experimental and control
group, at the level of p#0.05, **p#0.01 and, ***p#0.001.
doi:10.1371/journal.pone.0102624.g003
Figure 4. Immunoblot validation of protein markers in plasma.
The immunoblot and validation analysis for (A) galectin-3 and (B)
histone H2B from plasma samples. The number of samples in validation:
CTR n= 16, HP n= 10, SARC n=11. The means are shown in scatter
plots. *Indicates statistical significance, which is shown between
experimental and control group, at the level of p#0.05, **p#0.01
and, ***p#0.001.
doi:10.1371/journal.pone.0102624.g004
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handled similarly and they have not been thawed and re-frozen,
which has been shown to affect the stability of the proteins most
[33]. There are substantial differences in the storage times between
the samples from FIOH and those from the Meltola Hospital.
However, no significant difference between the levels of validated
proteins was observed between the healthy control samples from
FIOH and those from Meltola Hospital (data not shown). It should
also be noted that the protein expression pattern in the HP group
mirrored that of the closely related AME group. If protein
degradation were to be an important factor then one would not
expect the protein levels in the HP and SARC groups to be greater
than those in the DBRI group. Our protein identifications also
seem to be comparable with the 2-DE results reported earlier from
BAL collected from patients with interstitial lung disease [23]. We
are thus confident that differences in the storage times did not
influence the results in any substantial manner.
In general, there was less extensive lymphocytosis in the DBRI
samples than in the case of AME and HP (Table 1). The total cell
numbers and proportion of lymphocytes exceeded the normal
range only in half of our studied DBRI research samples.
However, samples chosen for DIGE analysis from DBRI group
did display lymphocytosis comparable to the AME and HP groups
(Figure S2) indicating that additional factors other than the
numbers of inflammatory cells were responsible for the difference
between the DBRI and AME/HP groups. Thus the proteomic
analysis suggests that the DBRI, at least its usual clinical
presentation, is distinct from HP and HP-like conditions.
However, it is possible that the proteomic pattern in an initial
phase of DBRI display more similarities with HP and AME, in
addition the exposure to damp buildings can sometimes cause
clinical HP [16].
We have earlier shown that DBRI is associated with a
lymphocytosis in BAL fluid [16]. In this study the relative lack
of protein changes in DBRI, although lymphocytosis was present,
can be seen to be in parallel with an earlier report where no HP
ensued in asymptomatic dairy farmers although they demonstrat-
ed increased BAL lymphocyte levels because of exposure to moldy
hay [34]. Thus the lymphocytosis in DBRI can be seen as a non-
pathologic response to inhaled NIMPs, not associated to an illness
like HP.
It would definitely be interesting to compare the proteomic
changes of a NIMP exposure in those persons that did develop an
illness with those that did not. There are however a number of
practical and ethical considerations which would make this an
extremely difficult proposition. In fact the study mentioned earlier
[34] is the only one where BAL has been obtained from this type
of healthy NIMP exposed individuals. Thus our study is limited to
pathologic conditions associated with the exposure to NIMPs, not
the normal response to inhaled NIMPs.
Samples from patients with sarcoidosis served as a reference for
a lung disease which has no direct association with NIMP
exposure. However, an epidemiologic relationship has been
observed between rural living and sarcoidosis [35]. According to
DeCyder data the protein expression pattern of SARC resembled
more that of control and DBRI than AME and HP, whereas the
levels of immunoblot validated proteins showed similar kinds of
elevation in both SARC and HP groups. This apparent
discrepancy could be explained by the fact that the DeCyder
process does not necessarily identify all proteoforms, which can be
detected by antibody-based methods.
When collecting a BAL specimen from a patient with interstitial
lung disease active lung infections are avoided as they will make
the interpretation of the results almost impossible. Accordingly,
there was no significant neutrophilia associated with any of the
groups (Table 1). This more or less excludes the possibility that the
measured changes were influenced by infections. Albumin levels
did vary between the groups and was highest in the SARC group
and the lowest in the CTR group (Table 1). It is well known that
albumin levels increase in interstitial lung inflammations and can
be seen to validate the selection of the patient groups [36,37].
Immunoglobulin G levels are often used in clinical practice to
help in the evaluation of the BAL samples. In our study, the IgG
expression levels were high in the patients exposed NIMPs in
agricultural environment and in patients suffering from sarcoidosis
or hypersensitivity pneumonia as compared to healthy persons.
These results are consistent with the earlier results reported in the
literature [38] and indicate that the BAL fluid samples used were
truly representative.
In the validation study, we selected the markers that increased
with reasonable robustness relative to the healthy controls. The
selected proteins included one novelty and other proteins
‘‘without’’ novelty i.e. molecules that could be considered as being
established inflammatory markers. The proteins were validated
from BAL samples of all five study groups, and from the plasma
samples available from CTR, HP and SARC groups.
The most interesting finding was the detection of semenogelin I
in BAL fluid in AME and HP, and also in sarcoidosis patients.
Attempts to validate the semenogelin from plasma gave inconsis-
tent results, possibly due to too low levels of the target protein.
Semenogelin I and II are the major products secreted from the
glandular epithelium of the seminal vesicles and the epididymis,
that together with fibronectin, give rise to the gel-like coagulum of
the newly ejaculated semen [39]. In addition, fragments of
semenogelin have been claimed to possess antimicrobial effects
[40,41] and heparin binding properties in human seminal plasma
[42]. It has also been observed that semenogelin has a high zinc
ionbinding capacity thus possibly functioning as a regulator for
zinc homeostasis [43]. Semenogelin expression has also been
observed in non-genital tissues including trachea and bronchi [44].
Semenogelin I and II were identified in asthmatic chronic
rhinosinusitis nasal lavage fluid, but were not observed in allergic
rhinitis nasal lavage fluid [45]. There are also studies pointing to
the involvement of semenogelins in different type of cancers such
as small cell lung carcinoma [31,46,47]. Our observation seems to
be the first demonstration where semenogelin is identified in
bronchoalveolar lavage fluid of interstitial lung disease patients
and patients exposed to inhaled non-infectious microbial particles.
One possible role for semenogelin is its regulation of mucus
viscosity which could be seen as a component of microbial
defence. For example, changes in mucus viscosity may impair
mucus clearance in the airways and lungs. Deficient mucus
clearance is associated to lung bacterial infections and other
respiratory diseases [48]. Regulation of zinc homeostasis is another
possible mechanism of action. The lungs are directly exposed to
higher oxygen concentrations than most other tissues and it has
been shown that depletion of labile zinc renders airway epithelial
cells highly susceptible to the apoptosis induced by oxidants
[49,50]. The allergic inflammation is also linked to perturbation in
zinc homeostasis [51].
For histone component H4, significantly increased expression in
BAL fluid was associated with AME, HP and SARC patient
samples. Interestingly, the levels of other histone variant, H2B
were increased in plasma samples of HP and SARC patients,
whereas H4 we could not detect from plasma. Histones form the
core component of the nucleosome, which is the central part of
double-represented histones H2A–H2B and H3–H4 [52]. The
small amounts of nucleosomes found in serum of healthy persons
are attributable to release upon physiological cell death. Elevated
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levels of nucleosomes are observed in blood in diseases in which
enhanced cell death has been reported to be present [53]. Elevated
levels of histones have been observed in association with a
common lung disease, chronic obstructive pulmonary disease
(COPD) [54]. Histones function as damage associated molecular
patterns (DAMPs) which trigger inflammation and they have been
shown to play a central role in hyperinflammatory syndromes,
mediating death in a mouse model of sepsis [32,55]. Based on the
present results of elevated histone levels in BAL and plasma it can
be speculated that histones may play a role in the pathogenesis of
interstitial lung diseases or conditions associated with inhaled
NIMPs.
The size of detected histones in BAL samples were aberrant,
which might be due to altered post-translational modification of
these proteins. Post-translational modification of histones by
phosphorylation, acetylation, methylation and ubiquination are
processes which regulate chromatin structure and gene expression.
Histone 4 has also been shown to be modified by SUMO (Small
Ubiquitin-like Modifier), which can modulate deacetylase activity
and thus influence transcriptional repression [56]. The attached
SUMO proteins can increase the molecular weight of the other
proteins depending on their number in the linked chain [57]. It
needs to be clarified whether inhaled NIMPs can cause the
appearance of aberrant size histones in BAL fluid and possible
activation of post-translational modification.
The levels of galectin-3 were elevated in all of the studied lung
diseases, with the highest expression of galectin-3 being observed
in AME patients. Interestingly in DBRI, the galectin-3 levels were
increased with a higher degree of statistical significance than for
alpha-1-antitrypsin, which is a well-known indicator of lung
inflammation. In contrast, there were no significant differences in
galectin-3 levels compared to healthy controls in plasma samples
of HP and SARC patients. Galectins are highly conserved family
of lectins, which have binding affinity for b-galactosides [58].
During the tissue damage cytosolic galectins are passively released
by dying cells or actively secreted by inflammatory activated cells
[59]. Galectin-3 is considered as a potential damage associated
molecular pattern (DAMP) and can also act as pattern recognition
receptors (PRR), which binds to the glycans present on the cell
walls of microorganisms [59]. Galectin-3 is involved in many
innate immune response activating processes: chemoattraction of
monocytes and macrophages [60], oxidative burst of neutrophils
[61] and mast-cell degranulation [62]. Earlier studies have been
shown increased levels of galectin-3 linked to inflammation or
microbial infection in lungs. It was also reported to play an
essential role in the development of lower airway hyperrespon-
siveness [63–66]. In acute inflammation, galectin-3 is increased
and seems to have a pro-inflammatory role. However, if the
inflammation progresses to a more chronic stage, galectin-3 has
been reported to facilitate the walling-off process of tissue injury
with fibrogenesis and organ scarring [67]. There are reports where
galectin-3 has been utilized as a marker to follow the inflammatory
activity of a disease or used as a factor for prognosis in cancers or
chronic heart failure [68–70]. Serum levels of galectin-3 have been
used to monitor the inflammatory stage of inflammatory bowel
disease [71]. Our finding that the expression of galectin-3 is
increased in HP and SARC in BAL is in line with its role in
inflammation.
The BAL levels of alpha-1-antitrypsin (A1AT) were elevated in
all groups with illnesses including DBRI. We could not detect
A1AT from plasma possibly due to too low levels of the target
protein. A1AT is an inhibitor of serine proteases and it is one of
the plasma proteins which make up the acute phase proteins. One
important physiological function of antitrypsin is to protect the
lower respiratory tract against proteolytic destruction by human
leukocyte elastase (HLE) [72]. A1AT deficiency may cause severe
emphysema [73]. Patients with A1AT deficiency are also known to
be hyperresponsive to organic dust exposure [74]. Recently, A1AT
has been shown to have anti-inflammatory and tissue protective
properties independent of its protease inhibitory effects [75,76].
A1AT appears to be antibacterial and to act as an inhibitor agent
in viral infections [77,78]. It is mainly synthesized in liver, but
interstitial A1AT in lungs is primarily produced by lung type II
alveolar epithelial cells [79]. A1AT has been detected and found to
increase in BAL of patients with interstitial lung disease in
previously published proteomic studies of lung diseases [80–82]
and its levels increase in association with different pulmonary
exposures [83].
The healthy lung is classically thought to be sterile but recent
studies have suggested that the lung possesses its own microbiome
[84,85], thus lung is in continuous interaction with microbial
structures of its own microbiome. It has been demonstrated that
there are differences in microbial composition of the airway flora
between healthy lungs and those with chronic lung diseases, such
as asthma, chronic obstructive pulmonary disease as well as cystic
fibrosis [85–87]. In the future, it would be interesting to study the
possible alterations in the lung microbiome associated with
exposure to NIMPs and its contribution in protection or
progression of this type of lung diseases.
Conclusions
Taken together, the results from the 2D-gel analysis and the
validation studies suggest that at least the typical case of DBRI,
where the main symptom is asthma and/or an increased sensitivity
to poor indoor air quality, is not closely related to AME and HP.
This result was somewhat unexpected as all of these conditions are
associated with the exposure to NIMPs and that the symptoms
between the DBRI group and the AME group are rather similar.
A possible explanation for the difference of DBRI and AME is that
they affect separate parts of the airways, HP is known to affect the
alveolar space while DBRI seems to affect the more proximal
airways. We could detect increases in the levels of several proteins
of interest that could be considered as markers of inflammation.
Increases in the levels of some indicators of inflammation (alpha-1-
antitrypsin, galectin-3) could also be demonstrated in the DBRI
group. However, none of the identified proteins can be considered
as being specific for illnesses associated with NIMPs. One of the
novel findings was the high levels of semenogelin detected in BAL
fluid from patients suffering from HP or AME. The detectability of
histones (H2B) in plasma in HP and SARC suggest H2B to be a
marker for the inflammation in the lungs. In future, prospective
studies it would be interesting to analyze histones in blood also in
DBRI and AME groups. As histones have been claimed to possess
a pathogenic role in severe inflammations (sepsis) development of
histone specific therapies and monitoring may be beneficial. The
study also demonstrates the advantages of using of bronchoalve-
olar lavage samples for proteomic studies of changes in alveolar
lining fluid associated to exposure of non-infectious microbial
particles. Viewed from a clinical point of view, these results suggest
that the BAL analysis of protein markers (including semenogelin I,
H4 and total IgG) could be helpful in the differential diagnosis
between DBRI and HP, especially when lymphocytosis is present
in the BAL fluid. Furthermore, the determination of galectin-3
levels in BAL fluid might be useful for evaluating the condition of
DBRI patients.
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